Better Use Of Phase II Trials Urged By FDA Statistician O'Neill
Executive Summary
FDA is reiterating the value of conducting a robust Phase II program as part of its discussions of adaptive trial designs, as the agency tries to urge sponsors to conduct sufficient exploratory trials to support successful Phase III trials